• Text size
  • Normal
  • Big


Healios is engaged in the development of cellular and tissue-based products, which are expected to be novel therapies for various diseases. We will simultaneously encourage work in expanding our small molecule compound drug technology BBG250.
Below are the product pipelines we are currently working on.

Development pipelines

Development of an ophthalmic surgery stain using BBG250 as a major component (already available in Europe as a CE Mark product).

Development pipelines

Development pipelines
Please refer to the page Development of Treatments for Age-Related Macular Degeneration (AMD) involving transplantation of iPS cell-derived retinal pigment epithelial (RPE) cells as an iPSC regenerative medicine.

Development pipelines
Please refer to the page Development of Organ Anlage Transplantation Therapy involving a technology to create functional human organs using pluripotent stem cells (such as iPS cells).

Development pipelines
Development of regenerative medicine using MultiStem for ischemic stroke.


  1. In Indication column, wet AMD refers to exudative age-related macular degeneration and dry AMD refers to atrophic age-related macular degeneration.
  2. HLM0022 is registered as a CE (Conformité Européenne) Mark product, which is a certification for manufacturing and distributing medical devices in Europe. It is manufactured and distributed by DORC (Dutch Ophthalmic Research Center International) under license.
  3. Healios is seeking conditional approval for HLCR011 under newly established regulations for conditional and temporary approval (“conditional approval”) for cellular and tissue-based products (Article 23 and Article 26, Clause 1 of the revised Pharmaceutical Affairs Law).